SEC Comment Letter 0000000000-25-000806 to Phio Pharmaceuticals Corp. (PHIO)
Phio Pharmaceuticals Corp.
Date: Jan. 24, 2025 · CIK: 0001533040 · Accession: 0000000000-25-000806
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-284381
Letter
January 24, 2025 Robert Bitterman Chief Executive Officer Phio Pharmaceuticals Corp. 11 Apex Drive, Suite 300A, PMB 2006 Marlborough, Massachusetts 01752 Re:Phio Pharmaceuticals Corp. Registration Statement on Form S-1 Filed January 21, 2025 File No. 333-284381 Dear Robert Bitterman: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tamika Sheppard at 202-551-8346 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Amanda Brown, Esq.
Show Raw Text
January 24, 2025
Robert Bitterman
Chief Executive Officer
Phio Pharmaceuticals Corp.
11 Apex Drive, Suite 300A, PMB 2006
Marlborough, Massachusetts 01752
Re:Phio Pharmaceuticals Corp.
Registration Statement on Form S-1
Filed January 21, 2025
File No. 333-284381
Dear Robert Bitterman:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tamika Sheppard at 202-551-8346 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Amanda Brown, Esq.